跳至主要内容
临床试验/NCT05353673
NCT05353673Unknown2 期

The Combination of Sitagliptin and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia: A Randomized, Controlled, Multicenter, Open-label Trial

Peking University People's Hospital1 个研究点 分布在 1 个国家目标入组 120 人开始时间: 2021年6月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
入组人数
120
试验地点
1
主要终点
Sustained response

研究概览

简要总结

Randomized, open-label, multicenter study to compare the efficacy and safety of combination of Sitagliptin and danazol versus danazol for the treatment of adults with steroid-resistant/relapse immune thrombocytopenia (ITP).

详细描述

The investigators are undertaking a parallel group, multicenter, randomized controlled trial of 120 adults with steroid-resistant/relapse ITP in China. Patients were randomized to Sitagliptin plus danazol and danazol monotherapy group. Platelet count, bleeding and other symptoms were evaluated before and after treatment. Adverse events are also recorded throughout the study.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Primary immune thrombocytopenia (ITP) confirmed by excluding other supervened causes of thrombocytopenia; Platelet count of less than 30×109/L at enrollment; Patients who did not achieve a sustained response to treatment with full-dose corticosteroids for a minimum duration of 4 weeks or who relapsed during steroid-tapering or after its discontinuation; 18 years older;

排除标准

  • Secondary immune thrombocytopenia (e.g., patients with HIV, HCV, Helicobacter pylori infection or patients with systemic lupus erythematosus) Congestive heart failure Severe arrhythmia Nursing or pregnant women Aspartate aminotransferase and alanine transaminase levels ≥ 3× the upper limit of the normal threshold criteria Creatinine or serum bilirubin levels each 1•5 times or more than the normal range Active or previous malignancy Unable to do blood routine test for the sake of time, distance, economic issues or other reasons.

研究组 & 干预措施

Sitagliptin and Danazol

Experimental

Sitagliptin is given at a dose of 100 mg/m2 qd for 12 weeks. Danazol is given at 200mg bid for 12 weeks.

干预措施: Sitagliptin (Drug)

Sitagliptin and Danazol

Experimental

Sitagliptin is given at a dose of 100 mg/m2 qd for 12 weeks. Danazol is given at 200mg bid for 12 weeks.

干预措施: Danazol (Drug)

Danazol

Active Comparator

Danazol is given at 200mg bid for 12 weeks.

干预措施: Danazol (Drug)

结局指标

主要结局

Sustained response

时间窗: 6 months

The maintenance of platelet count ≥ 30 x 10\^9/L, at least 2-fold increase of the baseline count, the absence of bleeding, and no need for rescue medication at the 6-month follow-up. Interim analysis was scheduled at 50% through recruitment.

次要结局

  • Duration of response(6 months)
  • Partial remission(6 months)
  • Incidence of treatment-emergent adverse events(6 months)
  • Time to response(6 months)
  • Complete remission(6 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Xiao Hui Zhang

Vice president of Peking Univeristy Institute of Hematology

Peking University People's Hospital

研究点 (1)

Loading locations...

相似试验